此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

2018年7月31日 更新者：Novo Nordisk A/S

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus

This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

635

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 日本
      • Annaka-shi, Gunma、日本、379 0116
        • Novo Nordisk Investigational Site
      • Chitose, Hokkaido、日本、066-0032
        • Novo Nordisk Investigational Site
      • Chuo-ku Tokyo、日本、103-0027
        • Novo Nordisk Investigational Site
      • Chuo-ku,、日本、104 0061
        • Novo Nordisk Investigational Site
      • Chuo-ku, Tokyo、日本、103 0027
        • Novo Nordisk Investigational Site
      • Chuo-ku, Tokyo、日本、103 0002
        • Novo Nordisk Investigational Site
      • Fukuoka-shi, Fukuoka、日本
        • Novo Nordisk Investigational Site
      • Higashiosaka-shi, Osaka、日本
        • Novo Nordisk Investigational Site
      • Hokkaido、日本、078-8236
        • Novo Nordisk Investigational Site
      • Ichikawa-shi, Chiba、日本
        • Novo Nordisk Investigational Site
      • Iruma-shi, Saitama、日本、358 0011
        • Novo Nordisk Investigational Site
      • Izumisano-shi、日本、598 0048
        • Novo Nordisk Investigational Site
      • Kashiwara-shi, Osaka、日本、582 0005
        • Novo Nordisk Investigational Site
      • Kawagoe-shi, Saitama、日本、350 0851
        • Novo Nordisk Investigational Site
      • Kobe-shi, Hyogo、日本
        • Novo Nordisk Investigational Site
      • Kumamoto-shi,Kumamoto、日本、862 0976
        • Novo Nordisk Investigational Site
      • Mito-shi, Ibaraki、日本、310-0845
        • Novo Nordisk Investigational Site
      • Mito-shi, Ibaraki、日本
        • Novo Nordisk Investigational Site
      • Miyazaki-shi、日本、880 0034
        • Novo Nordisk Investigational Site
      • Naka-shi, Ibaraki、日本、311 0113
        • Novo Nordisk Investigational Site
      • Neyagawa-shi, Osaka、日本
        • Novo Nordisk Investigational Site
      • Nishinomiya-shi, Hygo、日本、662 0971
        • Novo Nordisk Investigational Site
      • Nishinomiya-shi, Hyogo、日本、663-8501
        • Novo Nordisk Investigational Site
      • Oita-shi、日本、870 0039
        • Novo Nordisk Investigational Site
      • Okawa-shi, Fukuoka、日本、831 0016
        • Novo Nordisk Investigational Site
      • Osaka-shi, Osaka、日本、553 0003
        • Novo Nordisk Investigational Site
      • Osaka-shi, Osaka、日本、5590012
        • Novo Nordisk Investigational Site
      • Oyama-shi, Tochigi、日本、323 0022
        • Novo Nordisk Investigational Site
      • Saga-shi,Saga、日本、849 0937
        • Novo Nordisk Investigational Site
      • Sapporo-shi, Hokkaido、日本、060 0062
        • Novo Nordisk Investigational Site
      • Sapporo-shi, Hokkaido、日本、060-0001
        • Novo Nordisk Investigational Site
      • Sapporo-shi, Hokkaido、日本、062 0007
        • Novo Nordisk Investigational Site
      • Sappro-shi, Hokkaido、日本、060 8648
        • Novo Nordisk Investigational Site
      • Shimotsuke-shi, Tochigi、日本、329 0433
        • Novo Nordisk Investigational Site
      • Shinjuku-ku, Tokyo、日本、160-0008
        • Novo Nordisk Investigational Site
      • Shizuoka-shi、日本、424 0853
        • Novo Nordisk Investigational Site
      • Suita-shi, Osaka、日本、565-0853
        • Novo Nordisk Investigational Site
      • Takatsuki-shi, Osaka、日本、569 1096
        • Novo Nordisk Investigational Site
      • Tokyo、日本、181-0013
        • Novo Nordisk Investigational Site
      • Tokyo、日本、103-0028
        • Novo Nordisk Investigational Site
      • Tokyo、日本、169-0073
        • Novo Nordisk Investigational Site
      • Tokyo、日本、105-8471
        • Novo Nordisk Investigational Site
      • Tokyo、日本、123-0845
        • Novo Nordisk Investigational Site
      • Tokyo、日本、144-0051
        • Novo Nordisk Investigational Site
      • Yokohama, Kanagawa、日本、236-0004
        • Novo Nordisk Investigational Site
      • Yokohama-shi、日本、235 0045
        • Novo Nordisk Investigational Site
      • Yokohama-shi Kanagawa、日本、232-0064
        • Novo Nordisk Investigational Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female Japanese subjects at least 20 years of age at the time of informed consent
  • Type 2 diabetes subjects (diagnosed clinically) for at least 6 months prior to screening
  • HbA1c 7.5-10.0% [58 mmol/mol-86 mmol/mol] (both inclusive)
  • Subjects on stable therapy with one OAD (oral antidiabetic drug) (stable therapy is defined as unchanged medication and unchanged dose) for for at least 60 days before screening according to approved Japanese labelling

Exclusion Criteria:

  • Treatment with insulin within 12 weeks prior to screening
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening
  • Screening calcitonin equal or above 50 ng/l
  • History of pancreatitis (acute or chronic)
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Subjects presently classified as being in New York Heart Association (NYHA) Class IV
  • Within the past 180 days any of the following: myocardial infarction, stroke or hospitalisation for unstable angina and/or transient ischemic attack
  • Diagnosis of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer, polyps and in-situ carcinomas)
  • Any condition which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Liraglutide 1.8 mg
The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
药品：liraglutide
Injected subcutaneously s.c. (under the skin) once daily.
有源比较器：Liraglutide 0.9 mg
The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
药品：liraglutide
Injected subcutaneously s.c. (under the skin) once daily.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change in Glycosylated Haemoglobin (HbA1c) (Week 26)
大体时间：Week 0, Week 26
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of treatment. The change from baseline in the response after 26 weeks of treatment is analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline response as a covariate.
Week 0, Week 26

次要结果测量

结果测量
措施说明
大体时间
Change in HbA1c (Week 52)
大体时间：Week 0, Week 52
Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment.
Week 0, Week 52
Responder for HbA1c Below 7.0% (53 mmol/Mol)
大体时间：Week 26 and Week 52
Reported results are number of subjects who achieved HbA1c target below 7.0% after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Responder for HbA1c Below or Equal to 6.5% (48 mmol/Mol)
大体时间：Week 26 and Week 52
Reported results are number of subjects who achieved HbA1c target below or equal to 6.5% after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Responder for HbA1c Below 7.0% Without Weight Gain
大体时间：Week 26 and Week 52
Reported results are number of subjects who achieved HbA1c target below 7.0% without weight gain after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Responder for HbA1c Below 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
大体时间：Week 26 and Week 52
Reported results are subjects with HbA1c <7.0% after 26 weeks and 52 weeks of treatment, respectively without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. Severe or BG confirmed symptomatic hypoglycaemia: severe as per ADA classification or BG confirmed by plasma glucose (PG) value <3.1 mmol/L with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA: episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk)0) and no later than 7 days after the last day on liraglutide (maximum till wk26+7days and wk52+7days). Hence, the following shown 'Time Frame' should be read as 'Wk26+7days and Wk52+7days'
Week 26 and Week 52
Change in Self-Measured Blood Glucose (SMBG) 7-point Profile: 7-point Profile (Individual Points in the Profile)
大体时间：Week 0 and Week 26 and Week 52

Reported results are 7-point SMBG values at week 0, week 26 and week 52. The 7-point profile blood glucose levels were measured at the following time points always starting with the first:

  1. Before breakfast.
  2. 90 minutes after start of breakfast.
  3. Before lunch.
  4. 90 minutes after start of lunch.
  5. Before dinner.
  6. 90 minutes after start of dinner.
  7. At bedtime.
Week 0 and Week 26 and Week 52
Change in SMBG 7-point Profile: Mean of 7-point Profile
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in mean of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in SMBG 7-point Profile: Mean of Postprandial Increments (From Before Meal to 90 Minutes After for Breakfast, Lunch and Dinner)
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in mean of postprandial increments (from before meal to 90 minutes after for breakfast, lunch and dinner) of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Fasting Plasma Glucose (FPG)
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in FPG was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Waist Circumference
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in waist circumference was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Body Weight
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in body weight was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Body Mass Index (BMI)
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in BMI was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Blood Pressure (Systolic and Diastolic)
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Fasting C-peptide
大体时间：Week 26 and Week 52
Fasting C-peptide was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Fasting Insulin
大体时间：Week 26 and Week 52
Fasting insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Fasting Glucagon
大体时间：Week 26 and Week 52
Fasting glucagon was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Proinsulin
大体时间：Week 26 and Week 52
Proinsulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Proinsulin/Insulin
大体时间：Week 26 and Week 52
Proinsulin/insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Homeostasis Model Assessment of Beta-cell Function (HOMA-B)
大体时间：Week 26 and Week 52
HOMA-B was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B=[(20 x fasting insulin in µU/mL)/(FPG in mmol/L-3.5)].
Week 26 and Week 52
Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)
大体时间：Week 26 and Week 52
HOMA-IR was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-IR is an index of insulin resistance and was calculated as: HOMA-IR= fasting insulin (μU/mL) x FPG (mmol/L)/22.5.
Week 26 and Week 52
Total Cholesterol
大体时间：Week 26 and Week 52
Total cholesterol was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Low Density Lipoprotein (LDL) Cholesterol
大体时间：Week 26 and Week 52
LDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
High Density Lipoprotein (HDL) Cholesterol
大体时间：Week 26 and Week 52
HDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Very Low Density Lipoprotein (VLDL) Cholesterol
大体时间：Week 26 and Week 52
VLDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Triglycerides
大体时间：Week 26 and Week 52
Triglycerides were evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Free Fatty Acids
大体时间：Week 26 and Week 52
Free fatty acids were evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 26 and Week 52
Number of Treatment Emergent Adverse Events
大体时间：Weeks 0-26 and Weeks 0-52
Treatment emergent adverse events (TEAEs) were evaluated during the 26-week and 52-week treatment period, respectively. TEAE for weeks 0-26: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 26 + 7 days). TEAE for weeks 0-52: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 52 + 7 days). Hence, the following shown 'Time Frame' should be read as 'Weeks 0-26 + 7 days and Weeks 0-52 + 7 days'.
Weeks 0-26 and Weeks 0-52
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
大体时间：Weeks 0-26 and Weeks 0-52
Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the 26-week and 52-week treatment period, respectively. Severe or BG confirmed symptomatic hypoglycaemia (hypo):An episode that was severe according to the ADA classification or BG confirmed by a PG value <3.1 mmol/L with symptoms consistent with hypo. ADA definition of severe hypo:episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk) 0) and no later than 7 days after the last day on liraglutide (maximum till wk 26 and wk 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'wk 0-26+7 days and wk 0-52+7 days'.
Weeks 0-26 and Weeks 0-52
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
大体时间：Weeks 0-26 and Weeks 0-52
Treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the26-week and 52-week treatment period, respectively. Nocturnal hypoglycaemic episodes: Those occurring between 00:01 and 05:59 hours, both inclusive. Severe or BG confirmed symptomatic hypoglycaemia: episode that was severe according to the ADA classification or BG confirmed by a PG value <3.1 mmol/L with symptoms consistent with hypoglycaemia. Treatment emergent: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
Weeks 0-26 and Weeks 0-52
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition
大体时间：Weeks 0-26 and Weeks 0-52

American Diabetes Association (ADA) classification of hypoglycaemia:

  1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.
  2. Documented symptomatic: PG level ≤3.9 mmol/L with symptoms.
  3. Asymptomatic: PG level ≤3.9 mmol/L without symptoms.
  4. Probable symptomatic: No measurement with symptoms.
  5. Pseudo: PG level >3.9 mmol/L with symptoms. Treatment emergent hypoglycaemic episode: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
Weeks 0-26 and Weeks 0-52
Change in Pulse
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in pulse was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Physical Examination
大体时间：Week 0 and Week 26 and Week 52

Reported results are physical examination outcomes at week (wk) 0, wk 26 and wk 52. Physical examination consisted of the following listed examinations and the outcome of each examination was evaluated as: 1) normal, 2) abnormal, not clinically significant (NCS) or 3) abnormal, clinically significant (CS).

  1. Cardiovascular system
  2. Central and peripheral nervous system (PNS)
  3. Gastrointestinal (GI) system including mouth
  4. General appearance
  5. Head, ears, eyes, nose, throat, neck
  6. Lymph node palpation
  7. Musculoskeletal system
  8. Respiratory system
  9. Skin
  10. Thyroid gland
Week 0 and Week 26 and Week 52
Change in Eye Examination
大体时间：Week 0 and Week 26 and Week 52
Reported results are eye examination (ophthalmoscopy) outcomes at week 0, week 26 and week 52. Ophthalmoscopy outcomes for both left and right eye were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
Week 0 and Week 26 and Week 52
Change in Electrocardiogram (ECG)
大体时间：Week 0 and Week 26 and Week 52
Reported results are ECG outcomes at week 0, week 26 and week 52. ECG outcomes were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
Week 0 and Week 26 and Week 52
Change in Biochemistry: Creatinine
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in creatinine was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: eGFR
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in estimated glomerular filtration rate (eGFR) was evaluated after 26 weeks and 52 weeks of treatment, respectively. eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, mL/min/1.73m^2.
Week 0, Week 26, Week 52
Change in Biochemistry: Alanine Aminotransferase
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in alanine aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Aspartate Aminotransferase
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in aspartate aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Alkaline Phosphatase
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in alkaline phosphatase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Sodium
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in sodium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Potassium
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in potassium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Albumin
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in albumin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Total Bilirubin
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Urea
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in urea was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Creatine Kinase
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in creatine kinase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Calcium
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Albumin Corrected Calcium
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in albumin corrected calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Amylase
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in amylase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Biochemistry: Lipase
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in lipase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Haematology: Haemoglobin
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26, Week 52
Change in Haematology: Haematocrit
大体时间：Week 0, Week 26, Week 52
Change from baseline (week 0) in haematocrit was evaluated after 26 weeks and 52 weeks of treatment, respectively. Haematocrit is the ratio of the volume of red blood cells to the total volume of blood.
Week 0, Week 26, Week 52
Change in Haematology: Thrombocytes
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in thrombocytes (platelets) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Erythrocytes
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Leukocytes
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in leukocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Eosinophils
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in eosinophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Neutrophils
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in neutrophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Basophils
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in basophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Monocytes
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in monocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Haematology: Lymphocytes
大体时间：Week 0, Week 26 and Week 52
Change from baseline (week 0) in lymphocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Week 0, Week 26 and Week 52
Change in Calcitonin
大体时间：Week 0 and Week 26 and Week 52
Reported results are number of subjects with low, normal or high calcitonin values at week 0, week 26 and week 52. Number of subjects analyzed = number of subjects contributed to the analysis for individual time point. Calcitonin values were categorised as low, normal or high.
Week 0 and Week 26 and Week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Novo Nordisk A/S

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年7月21日

初级完成 (实际的)

2017年5月2日

研究完成 (实际的)

2017年11月9日

研究注册日期

首次提交

2015年7月21日

首先提交符合 QC 标准的

2015年7月21日

首次发布 (估计)

2015年7月22日

研究记录更新

最后更新发布 (实际的)

2018年9月5日

上次提交的符合 QC 标准的更新

2018年7月31日

最后验证

2018年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • NN2211-4174
  • U1111-1164-5462 (其他标识符：WHO)
  • JapicCTI-152975 (注册表标识符：JAPIC)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅